Lawfuel – The Legl Newswire – NEW YORK, June 28, 2007 – The Brualdi La…

Lawfuel – The Legl Newswire – NEW YORK, June 28, 2007 – The Brualdi Law Firm announces that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York, on behalf of purchasers of Bristol Myers Squibb Company (“BMY” or the “Company”) (NYSE:BMY) securities during the period between March 22, 2006 and August 8, 2006, (the “Class Period”).

No class has yet been certified in the above action. Until a class is
certified, you are not represented by counsel unless you retain one. If
you purchased BMY common stock during the period described above, you
have certain rights, and have until no later than 60 days from June 20,
2007, in which to move for Lead Plaintiff status. Any member of the
purported class may move the Court to serve as lead plaintiff through
counsel of their choice, or may choose to do nothing and remain an
absent class member.

To be a member of the class you need not take any action at this time,
and you may retain counsel of your choice. If you wish to discuss this
action or have any questions concerning this Notice or your rights or
interests with respect to these matters, please contact Tali Leger,
Director of Shareholder Relations at The Brualdi Law Firm, 29 Broadway,
Suite 2400, New York, New York 10006, by telephone toll free at (877)
495-1877 or (212) 952-0602, by email to [email protected] or
visit our website at http://www.brualdilawfirm.com/

As alleged in the Complaint, on March 22, 2006, BMY announced that it,
along with Sanofi-Aventis SA, entered into a settlement agreement with
Apotex, Inc. (“Apotex”) to resolve a patent infringement lawsuit
(“Apotex Settlement”) related to the drug Plavix. The Complaint further
alleges that throughout the Class Period, BMY failed to disclose
material facts regarding the Apotex Settlement including: (1) that BMY
had relinquished material rights in connection with the settlement,
including the right to treble damages; (2) that if the Apotex
Settlement was not approved, Apotex could flood the market with its
generic version of Plavix; and (3) that BMY had negotiated improper
side agreements in connection with the Apotex Settlement.

On July 27, 2006, BMY revealed that the Antitrust Division of the
United States Department of Justice (“DOJ”) was conducting a criminal
investigation into the Apotex Settlement and, as alleged, as a result
of this disclosure, the price of BMY’s securities declined $1.95 per
share, or 7.5%, to close at $24.04 per share. On August 8, 2006, BMY
disclosed additional material facts regarding the Apotex Settlement. As
a result of this disclosure, it is alleged that BMY’s securities
declined $1.56 per share, or approximately 7%, to close at $21.21 per
share.

The Complaint also alleges that on May 10, 2007 BMY issued a press
release disclosing that the Company agreed to plead guilty to federal
charges of making false statements to a government agency in connection
with the Apotex Settlement.

-0-
CONTACT: The Brualdi Law Firm
Tali Leger, Director of Shareholder Relations
Toll Free: (877) 495-1877
(212) 952-0602
[email protected]

about us